Novavax Inc (NVAX)

$6.56 -0.09 (-1.35%)
Market Cap 1.06B
Revenue (ttm) 682.16M
Net Income (ttm) -187.50M
EPS (ttm) N/A
PE Ratio 2.51
Forward PE 2.68
Profit Margin -27.49%
Debt to Equity Ratio 0.00
Volume 5,433,400
Avg Vol 5,613,034
Day's Range N/A - N/A
Shares Out 161.97M
Stochastic %K 10%
Beta 2.50
Analysts Sell
Price Target $13.29

Company Profile

Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax...

Industry: Biotechnology
Sector: Healthcare
Phone: 240 268 2000
Address:
700 Quince Orchard Road, Gaithersburg, United States
Ninjutsu888
Ninjutsu888 Aug. 3 at 4:31 AM
$NVAX 26-34 % of the float is short according to various estimates. What could ignite this? Right at 6.50 support line. Earnings next Wednesday.
0 · Reply
Biotechlineup
Biotechlineup Aug. 3 at 4:13 AM
$NVAX imo Sanofi assemble! Sure looks they are putting together the ultimate team. Novavax subunit protein nano tech already presents the optimal viral pre fusion of any vaccine. Avoiding egg agglutination and antigenic shift vs egg or cell based vaccines. With enhanced immune function provided by the best adjuvant matrix m the presentation is powerful . Sanofi makes another strategic move with molecular clamp technology which just happens to be the absolute best and versatile technology to stabilize the pre fusion viral antigens super charging all of the Novavax attributes.
0 · Reply
Biotechlineup
Biotechlineup Aug. 3 at 3:53 AM
$NVAX Is molecular clamp uniquely positioned for commercial profit? That's a very insightful question! You're pointing to a key strategic consideration in the competitive vaccine landscape. While it's true that other companies have technologies for viral protein stabilization, the molecular clamp possesses several unique advantages that position it favorably for commercial success. Here's why, along with some important nuances: Advantages of the molecular clamp technology Platform Applicability: The molecular clamp isn't limited to a single virus. It's a platform technology that can be rapidly adapted to stabilize the key surface proteins of various viruses, particularly those that use trimeric fusion proteins like RSV, influenza, and coronaviruses. This broad applicability makes it a valuable tool for developing vaccines against both known and emerging threats (Disease X). Optimal Antigen Conformation: Its primary function is to lock these proteins in their optimal pre-fusion conform
0 · Reply
BearBull777
BearBull777 Aug. 3 at 3:21 AM
$NVAX Novafam, still quite
0 · Reply
Biotechlineup
Biotechlineup Aug. 3 at 2:54 AM
$NVAX primary application of molecular clamp technology is to stabilize viral proteins, particularly trimeric fusion proteins found on the surface of viruses like influenza, RSV, and coronaviruses. These proteins naturally transition between pre-fusion and post-fusion conformations. When applied to Novavax's recombinant subunit flu vaccine, the molecular clamp could further enhance its differentiation by providing: Superior protection: By stabilizing the flu virus's hemagglutinin (HA) protein in its most effective pre-fusion state, leading to even broader and more potent immune responses. Reduced impact of antigenic drift: By focusing the immune response on conserved regions of the HA protein that are less prone to mutation. Improved manufacturability and potential for combination vaccines: Streamlined production and purification of HA antigens, potentially paving the way for easier development of multivalent flu vaccines or combination vaccines targeting other respiratory viruses.
0 · Reply
DrSammy
DrSammy Aug. 3 at 1:39 AM
$NVAX So this Quarter, the revenue components are: Sanofi(175M) + Takeda(20M) + 10M Payment from Sanofi 2024 SLA + Royalties from Matrix-M/Product Sales (Per CFO J.Kelly) + Any Product sales, of course! Long term liabilities: Total around 370M : GAVI (~250-270M) quarterly 20M payments + UK (~80M) quarterly payment : 10M. Every Quarter, total long term liability is reduced by 30M -- Possible Sanofi deal update per recent Phase IV, PMC. -- Update on Commercialization of US/EU Markets by Sanofi for 2025-26. Sanofi's responsibility -- MTA/Integration Updates, Announced in 3rd Q of last yr (if any) -- Possible $$$ -- On CIC/Standalone FLU/C-19: imo, if they can get an initial payment that equals the sum of R&D/SG&A for the next six quarters, it's going to be awesome! Combined w/ Partial Reimbursement of PIII Part B activities relating to Clinical Trials (not including CMC related requirements that must go to 'Partner(s)') . -- Quality of SLA is important -- give him time to do his job!
1 · Reply
OneDollarBob
OneDollarBob Aug. 3 at 1:33 AM
$NVAX So why is it that RFK Jr. can ban mercury from vaccines…but can’t ban mRNA until they do more studies?
2 · Reply
Paulchowda
Paulchowda Aug. 3 at 1:02 AM
$NVAX he’s broke my heart for sure, thanks for that information, Mr. Wall Street now go get your shine box
1 · Reply
ManMartin
ManMartin Aug. 3 at 12:38 AM
$NVAX
0 · Reply
Dailyone
Dailyone Aug. 3 at 12:35 AM
$NVAX do we actually think news on the 6th is gonna drop? I mean the management of this company is questionable
1 · Reply
Latest News on NVAX
Novavax to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 30, 2025, 8:00 AM EDT - 3 days ago

Novavax to Report Second Quarter 2025 Financial Results on August 6, 2025

Novavax Shares Promising Results For Bird Flu Vaccine, Tested In Primates

Jul 24, 2025, 11:02 AM EDT - 9 days ago

Novavax Shares Promising Results For Bird Flu Vaccine, Tested In Primates

Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study

Jul 24, 2025, 8:00 AM EDT - 9 days ago

Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study

Novavax, Inc. (NVAX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Jun 11, 2025, 8:59 PM EDT - 7 weeks ago

Novavax, Inc. (NVAX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Novavax's COVID-flu combo and standalone flu shots improve immunity in late-stage study

Jun 11, 2025, 7:11 AM EDT - 7 weeks ago

Novavax's COVID-flu combo and standalone flu shots improve immunity in late-stage study

Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial

Jun 11, 2025, 7:00 AM EDT - 7 weeks ago

Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial

Vaccine actions and policy positions under US Health Secretary Kennedy

Jun 10, 2025, 10:45 AM EDT - 7 weeks ago

Vaccine actions and policy positions under US Health Secretary Kennedy

BNTX MRNA PFE

Vaccine stocks muted as Wall Street takes 'wait and watch' approach after Kennedy's shake-up

Jun 10, 2025, 9:30 AM EDT - 7 weeks ago

Vaccine stocks muted as Wall Street takes 'wait and watch' approach after Kennedy's shake-up

BNTX MRNA PFE

Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors.

Jun 10, 2025, 8:18 AM EDT - 7 weeks ago

Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors.

BNTX MRNA PFE SNY

Novavax to Participate in Upcoming Investor Conferences

May 29, 2025, 8:00 AM EDT - 2 months ago

Novavax to Participate in Upcoming Investor Conferences

Novavax: Nuvaxovid FDA Approval Unlocks Several Bullish Stimuli

May 21, 2025, 8:15 AM EDT - 2 months ago

Novavax: Nuvaxovid FDA Approval Unlocks Several Bullish Stimuli

Healthy Returns: Novavax scores narrower Covid vaccine approval after delay

May 20, 2025, 4:34 PM EDT - 2 months ago

Healthy Returns: Novavax scores narrower Covid vaccine approval after delay

Top Stock Movers Now: Tesla, AutoZone, Novavax, and More

May 19, 2025, 12:15 PM EDT - 2 months ago

Top Stock Movers Now: Tesla, AutoZone, Novavax, and More

AZO TSLA

Novavax Stock Rockets. FDA Finally Had Good News for the Covid-19 Vaccine Maker.

May 19, 2025, 9:27 AM EDT - 2 months ago

Novavax Stock Rockets. FDA Finally Had Good News for the Covid-19 Vaccine Maker.

Novavax shares jump after long-awaited FDA approval of its COVID-19 vaccine

May 19, 2025, 7:16 AM EDT - 2 months ago

Novavax shares jump after long-awaited FDA approval of its COVID-19 vaccine

U.S. FDA Approves BLA for Novavax's COVID-19 Vaccine

May 19, 2025, 7:00 AM EDT - 2 months ago

U.S. FDA Approves BLA for Novavax's COVID-19 Vaccine

FDA approves Novavax COVID vaccine with new conditions

May 17, 2025, 10:26 PM EDT - 2 months ago

FDA approves Novavax COVID vaccine with new conditions

Novavax, Inc. (NVAX) Presents at BofA Securities 2025 Health Care Conference (Transcript)

May 14, 2025, 10:46 PM EDT - 2 months ago

Novavax, Inc. (NVAX) Presents at BofA Securities 2025 Health Care Conference (Transcript)

Novavax: Initiating Hold Rating After Strong, But Misunderstood Q1 2025 Earnings Beat

May 12, 2025, 12:45 PM EDT - 2 months ago

Novavax: Initiating Hold Rating After Strong, But Misunderstood Q1 2025 Earnings Beat

COVID Vaccine Maker Novavax Stock Soars 16% - Here's Why

May 8, 2025, 1:31 PM EDT - 3 months ago

COVID Vaccine Maker Novavax Stock Soars 16% - Here's Why

Novavax, Inc. (NVAX) Q1 2025 Earnings Call Transcript

May 8, 2025, 11:48 AM EDT - 3 months ago

Novavax, Inc. (NVAX) Q1 2025 Earnings Call Transcript

Why This Shrinking Covid-19 Vaccine Stock Jumped 30%

May 8, 2025, 11:12 AM EDT - 3 months ago

Why This Shrinking Covid-19 Vaccine Stock Jumped 30%

Novavax swings to profit on lower expenses related to COVID shots

May 8, 2025, 8:06 AM EDT - 3 months ago

Novavax swings to profit on lower expenses related to COVID shots

Novavax Reports First Quarter 2025 Financial Results and Operational Highlights

May 8, 2025, 8:00 AM EDT - 3 months ago

Novavax Reports First Quarter 2025 Financial Results and Operational Highlights

New vaccine chief rocks pharmaceutical stocks

May 7, 2025, 11:13 AM EDT - 3 months ago

New vaccine chief rocks pharmaceutical stocks

BNTX MRNA PFE GSK IBB SRPT XBI

Novavax to Participate in BofA Securities 2025 Health Care Conference

May 7, 2025, 8:00 AM EDT - 3 months ago

Novavax to Participate in BofA Securities 2025 Health Care Conference

Novavax Announces Significantly Improved Terms for Collaboration and License Agreement with Takeda for Nuvaxovid® in Japan

May 5, 2025, 8:00 AM EDT - 3 months ago

Novavax Announces Significantly Improved Terms for Collaboration and License Agreement with Takeda for Nuvaxovid® in Japan

Novavax to Report First Quarter 2025 Financial Results on May 8, 2025

May 1, 2025, 8:00 AM EDT - 3 months ago

Novavax to Report First Quarter 2025 Financial Results on May 8, 2025

Novavax Appoints Charles Newton to Board of Directors

Apr 29, 2025, 8:00 AM EDT - 3 months ago

Novavax Appoints Charles Newton to Board of Directors

FDA asks Novavax to complete new clinical trial for delayed COVID-19 shot, WSJ reports

Apr 25, 2025, 3:35 PM EDT - 3 months ago

FDA asks Novavax to complete new clinical trial for delayed COVID-19 shot, WSJ reports

FDA Asks Vaccine Maker to Complete New Clinical Trial for Delayed Covid-19 Shot

Apr 25, 2025, 3:20 PM EDT - 3 months ago

FDA Asks Vaccine Maker to Complete New Clinical Trial for Delayed Covid-19 Shot

Insight: As FDA delays Novavax' COVID vaccine approval, patients fight back

Apr 24, 2025, 6:04 AM EDT - 3 months ago

Insight: As FDA delays Novavax' COVID vaccine approval, patients fight back

Novavax's COVID-19 Vaccine Nears FDA Full Approval, Stock Jumps

Apr 23, 2025, 5:00 PM EDT - 3 months ago

Novavax's COVID-19 Vaccine Nears FDA Full Approval, Stock Jumps

FDA asks Novavax for commitment on post-approval studies for COVID vaccine

Apr 23, 2025, 8:26 AM EDT - 3 months ago

FDA asks Novavax for commitment on post-approval studies for COVID vaccine

SHIELD-Utah Study Shows Novavax's COVID-19 Vaccine Induces Lower Reactogenicity Symptoms Compared to mRNA

Apr 15, 2025, 7:00 AM EDT - 3 months ago

SHIELD-Utah Study Shows Novavax's COVID-19 Vaccine Induces Lower Reactogenicity Symptoms Compared to mRNA

Novavax shares tumble after U.S. health secretary raises concerns over COVID shot's efficacy

Apr 10, 2025, 3:02 PM EDT - 4 months ago

Novavax shares tumble after U.S. health secretary raises concerns over COVID shot's efficacy

The FDA was moving to grant full approval for Novavax's Covid-19 vaccine. But it missed the April 1 deadline after the agency's vaccine chief was forced out.

Apr 2, 2025, 1:20 PM EDT - 4 months ago

The FDA was moving to grant full approval for Novavax's Covid-19 vaccine. But it missed the April 1 deadline after the agency's vaccine chief was forced out.

FDA misses deadline for decision on Novavax's COVID-19 vaccine, WSJ reports

Apr 2, 2025, 12:29 PM EDT - 4 months ago

FDA misses deadline for decision on Novavax's COVID-19 vaccine, WSJ reports

Vaccine stocks fall following FDA resignation

Mar 31, 2025, 6:21 PM EDT - 4 months ago

Vaccine stocks fall following FDA resignation

BNTX MRNA PFE PCVX PTCT XBI

Vaccine stocks tumble: Moderna, Novavax, Pfizer fall after top FDA official resigns over RFK Jr. anti-vax views

Mar 31, 2025, 2:41 PM EDT - 4 months ago

Vaccine stocks tumble: Moderna, Novavax, Pfizer fall after top FDA official resigns over RFK Jr. anti-vax views

BNTX MRNA PFE

Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul

Mar 31, 2025, 2:25 PM EDT - 4 months ago

Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul

BNTX SLDB SRPT TSHA XBI

Vaccine stocks fall after key FDA official resigns in protest of RFK Jr.

Mar 31, 2025, 10:13 AM EDT - 4 months ago

Vaccine stocks fall after key FDA official resigns in protest of RFK Jr.

BNTX MRNA PFE

Biotech stocks tumble on reports FDA's top vaccine regulator to leave

Mar 31, 2025, 7:25 AM EDT - 4 months ago

Biotech stocks tumble on reports FDA's top vaccine regulator to leave

BNTX MRNA PFE

Novavax, Inc. (NVAX) Leerink Partners 2025 Global Healthcare Conference (Transcript)

Mar 11, 2025, 7:48 PM EDT - 5 months ago

Novavax, Inc. (NVAX) Leerink Partners 2025 Global Healthcare Conference (Transcript)

Novavax Announces Changes to Board of Directors

Mar 11, 2025, 8:00 AM EDT - 5 months ago

Novavax Announces Changes to Board of Directors

Novavax, Inc. (NVAX) TD Cowen 45th Annual Health Care Conference (Transcript)

Mar 4, 2025, 1:34 PM EST - 5 months ago

Novavax, Inc. (NVAX) TD Cowen 45th Annual Health Care Conference (Transcript)

Novavax Q4 Earnings Review: Long-Term Downsizing Plan Suggests Sell Rating

Feb 28, 2025, 11:16 AM EST - 5 months ago

Novavax Q4 Earnings Review: Long-Term Downsizing Plan Suggests Sell Rating

Novavax to Participate in Upcoming March Investor Conferences

Feb 27, 2025, 4:05 PM EST - 5 months ago

Novavax to Participate in Upcoming March Investor Conferences

Novavax, Inc. (NVAX) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 11:42 AM EST - 5 months ago

Novavax, Inc. (NVAX) Q4 2024 Earnings Call Transcript

Novavax Reports Smaller Q4 Loss, Shifts Focus From Commercializing COVID-19 Vaccine To Maximize Value

Feb 27, 2025, 11:24 AM EST - 5 months ago

Novavax Reports Smaller Q4 Loss, Shifts Focus From Commercializing COVID-19 Vaccine To Maximize Value

Ninjutsu888
Ninjutsu888 Aug. 3 at 4:31 AM
$NVAX 26-34 % of the float is short according to various estimates. What could ignite this? Right at 6.50 support line. Earnings next Wednesday.
0 · Reply
Biotechlineup
Biotechlineup Aug. 3 at 4:13 AM
$NVAX imo Sanofi assemble! Sure looks they are putting together the ultimate team. Novavax subunit protein nano tech already presents the optimal viral pre fusion of any vaccine. Avoiding egg agglutination and antigenic shift vs egg or cell based vaccines. With enhanced immune function provided by the best adjuvant matrix m the presentation is powerful . Sanofi makes another strategic move with molecular clamp technology which just happens to be the absolute best and versatile technology to stabilize the pre fusion viral antigens super charging all of the Novavax attributes.
0 · Reply
Biotechlineup
Biotechlineup Aug. 3 at 3:53 AM
$NVAX Is molecular clamp uniquely positioned for commercial profit? That's a very insightful question! You're pointing to a key strategic consideration in the competitive vaccine landscape. While it's true that other companies have technologies for viral protein stabilization, the molecular clamp possesses several unique advantages that position it favorably for commercial success. Here's why, along with some important nuances: Advantages of the molecular clamp technology Platform Applicability: The molecular clamp isn't limited to a single virus. It's a platform technology that can be rapidly adapted to stabilize the key surface proteins of various viruses, particularly those that use trimeric fusion proteins like RSV, influenza, and coronaviruses. This broad applicability makes it a valuable tool for developing vaccines against both known and emerging threats (Disease X). Optimal Antigen Conformation: Its primary function is to lock these proteins in their optimal pre-fusion conform
0 · Reply
BearBull777
BearBull777 Aug. 3 at 3:21 AM
$NVAX Novafam, still quite
0 · Reply
Biotechlineup
Biotechlineup Aug. 3 at 2:54 AM
$NVAX primary application of molecular clamp technology is to stabilize viral proteins, particularly trimeric fusion proteins found on the surface of viruses like influenza, RSV, and coronaviruses. These proteins naturally transition between pre-fusion and post-fusion conformations. When applied to Novavax's recombinant subunit flu vaccine, the molecular clamp could further enhance its differentiation by providing: Superior protection: By stabilizing the flu virus's hemagglutinin (HA) protein in its most effective pre-fusion state, leading to even broader and more potent immune responses. Reduced impact of antigenic drift: By focusing the immune response on conserved regions of the HA protein that are less prone to mutation. Improved manufacturability and potential for combination vaccines: Streamlined production and purification of HA antigens, potentially paving the way for easier development of multivalent flu vaccines or combination vaccines targeting other respiratory viruses.
0 · Reply
DrSammy
DrSammy Aug. 3 at 1:39 AM
$NVAX So this Quarter, the revenue components are: Sanofi(175M) + Takeda(20M) + 10M Payment from Sanofi 2024 SLA + Royalties from Matrix-M/Product Sales (Per CFO J.Kelly) + Any Product sales, of course! Long term liabilities: Total around 370M : GAVI (~250-270M) quarterly 20M payments + UK (~80M) quarterly payment : 10M. Every Quarter, total long term liability is reduced by 30M -- Possible Sanofi deal update per recent Phase IV, PMC. -- Update on Commercialization of US/EU Markets by Sanofi for 2025-26. Sanofi's responsibility -- MTA/Integration Updates, Announced in 3rd Q of last yr (if any) -- Possible $$$ -- On CIC/Standalone FLU/C-19: imo, if they can get an initial payment that equals the sum of R&D/SG&A for the next six quarters, it's going to be awesome! Combined w/ Partial Reimbursement of PIII Part B activities relating to Clinical Trials (not including CMC related requirements that must go to 'Partner(s)') . -- Quality of SLA is important -- give him time to do his job!
1 · Reply
OneDollarBob
OneDollarBob Aug. 3 at 1:33 AM
$NVAX So why is it that RFK Jr. can ban mercury from vaccines…but can’t ban mRNA until they do more studies?
2 · Reply
Paulchowda
Paulchowda Aug. 3 at 1:02 AM
$NVAX he’s broke my heart for sure, thanks for that information, Mr. Wall Street now go get your shine box
1 · Reply
ManMartin
ManMartin Aug. 3 at 12:38 AM
$NVAX
0 · Reply
Dailyone
Dailyone Aug. 3 at 12:35 AM
$NVAX do we actually think news on the 6th is gonna drop? I mean the management of this company is questionable
1 · Reply
ManMartin
ManMartin Aug. 3 at 12:28 AM
$NVAX
0 · Reply
TaxEagle1040
TaxEagle1040 Aug. 3 at 12:24 AM
$NVAX Wrong again and again! The deal is coming! If you don't believe then sell!!!
0 · Reply
Huyderen
Huyderen Aug. 2 at 11:31 PM
$NVAX He has reported before open EVERY single time since he's the CEO.....
0 · Reply
dkallday
dkallday Aug. 2 at 9:46 PM
$NVAX https://x.com/leadingreport/status/1951706959897367014?s=46&t=PgVhn2nnit2y5e_qFRtjBA
1 · Reply
Stocks787
Stocks787 Aug. 2 at 9:28 PM
$NVAX $125.00 up
2 · Reply
Biotechlineup
Biotechlineup Aug. 2 at 7:20 PM
$NVAX I’m going to post my discussion with Google Gemini regarding the advantages of the Novavax flu vaccine vs Sanofi flu vaccines. The incredible advantages of molecular clamp technology which which I immediately understood , however could not detail. Seems no one on the internet understands it and its significance. Am I way off I asked ? We talked about egg adaptation and antigenic drift . I found understanding in Gemini. Result, I still may be nutty and totally off but more convinced than ever the Novavax CIC asset is incredibly valuable and giant leap forward. Absolutely perfect fit with Sanofi that said they are looking for further differentiation in flu vaccines. To the longs, I feel your pain , don’t give up yet.
9 · Reply
Nir43
Nir43 Aug. 2 at 5:13 PM
$NVAX Expensive Mistake, edios money&dreams
0 · Reply
Towe787
Towe787 Aug. 2 at 4:45 PM
$NVAX NVAX WE ARE NOT GOING ANYWHERE, IT WILL NOT FLY, THERE IS NO INDICATOR TO THE OPPOSITE.
4 · Reply
OneDollarBob
OneDollarBob Aug. 2 at 3:28 PM
$NVAX Who’s sticking around if JJ shits the bed again next week? I’ll probably just hold it , since it’s essentially worthless now anyway. Hoping for big news, but it seems the new administration has no intention of treating Novavax any differently than the last. While RFK Jr., Makary and Bhattacharya talked a big game before joining the Trump administration, they certainly seem to have had their minds changed about mRNA since. And don’t even get me started on JJ and the JV team.
5 · Reply
Barnstormer
Barnstormer Aug. 2 at 11:58 AM
$NVAX So JJ is reporting before the open? As I recall NVAX has almost always reported after the bell. I don't like to make too much of reporting times unless they deviate from the norm. I'll take it as a positive sign. GL2 all longs.
6 · Reply
Lazarus2024
Lazarus2024 Aug. 2 at 11:54 AM
$NVAX COVID increasing again because people aren’t getting vaccinated.
1 · Reply
pissed_of_retards
pissed_of_retards Aug. 2 at 11:44 AM
$NVAX Now the youtube video about seeking the partnership makes more sense in the light what Taylor said to biospace.
0 · Reply